分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Group 1 - Wharton Technology announced the establishment of a wholly-owned subsidiary, Wharton Technology (Nanjing) Co., Ltd., with an investment of 300 million yuan [1] - The investment decision was approved during the ninth meeting of the eighth board of directors held on November 21, 2025, and does not require shareholder approval [1] - The company’s revenue composition for the first half of 2025 includes: 62.64% from specialty chemicals manufacturing, 22.95% from plant fiber products manufacturing, 9.35% from membrane separation, 3.85% from reclaimed water reuse, and 1.21% from other businesses [1] Group 2 - As of the report date, Wharton Technology has a market capitalization of 5.8 billion yuan [1]

Core Viewpoint - Wharton Technology (000920.SZ) has approved the establishment of a wholly-owned subsidiary, Wharton Technology (Nanjing) Co., Ltd., with an investment of 300 million yuan from its own funds [1] Group 1 - The eighth board of directors' ninth meeting was held to review the proposal for the investment [1] - The investment amount for the new subsidiary is set at 30,000,000 yuan [1]

Core Viewpoint - Wharton Technology (000920.SZ) plans to invest 300 million yuan to establish a wholly-owned subsidiary, Wharton Technology (Nanjing) Co., Ltd., which will focus on enhancing the company's membrane materials and membrane components capabilities [1] Group 1 - The investment amount for the establishment of the subsidiary is 300 million yuan [1] - The new subsidiary, Nanjing Wharton, will serve as the investment and operational entity for the membrane materials and components enhancement project [1] - The project is currently in the planning stage [1]

Core Points - Wharton Technology (000920.SZ) announced plans to invest 300 million yuan to establish a wholly-owned subsidiary, Wharton Technology (Nanjing) Co., Ltd. [2] - The registered capital of the new subsidiary will also be 300 million yuan, and it will be located in Jiangbei New District, Nanjing, Jiangsu Province [2] - The business scope of the subsidiary includes research and development, production, sales, and technical services of reverse osmosis membranes, nanofiltration membranes, and other separation membrane materials [2] - This investment does not require shareholder approval, does not constitute a related party transaction, and is not classified as a major asset restructuring [2]

Core Viewpoint - Wharton Technology (000920.SZ) plans to invest 300 million yuan to establish a wholly-owned subsidiary, Wharton Technology (Nanjing) Co., Ltd., to enhance its membrane materials and membrane components capabilities [1] Group 1 - The investment amount for the establishment of the subsidiary is 300 million yuan [1] - The new subsidiary, Nanjing Wharton, will serve as the investment and operational entity for the company's membrane materials and components enhancement project [1] - The project is currently in the planning stage [1]

关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000920 证券简称：沃顿科技 公告编号：2025-060 沃顿科技股份有限公司 特别提示： 公司续聘会计师事务所符合《国有企业、上市公司选聘会计师事 务所管理办法》的规定。 一、拟续聘会计师事务所的基本情况 （一）机构信息 | 1.基本信息 | | --- | | 事务所名称 | 大信会计师事务所（特殊普通合伙） | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 年 2012 6 | 3 | 月 | 日 | | | | 组织形式 | 特殊普通合伙企业 | | | | | | | 注册地址 | 北京市海淀区知春路 1 号 | | | | 22 层 | 2206 | | 首席合伙人 | 谢泽敏 | | | | | | | 上年末合伙人数量 | 人 175 | | | | | | | 注册会计师人数 | 人 1031 | | | | | | | 签署过证券服务业务审计 | 超 500 | 人 | ...

一、对外投资概述 证券代码：000920 证券简称：沃顿科技 公告编号：2025-061 沃顿科技股份有限公司 关于对外投资设立全资子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日召开第八届董事会第九次会议，审议通过了《关于投资设立全资子 公司的议案》，公司拟以自有资金 30,000 万元投资设立全资子公司 沃顿科技（南京）有限公司（以下简称"南京沃顿"，最终名称以工 商登记为准）。根据《深圳证券交易所股票上市规则》、《公司章程》 等相关规定，本事项无需提交股东会审议。本事项不构成关联交易， 也不属于《上市公司重大资产重组管理办法》规定的重大资产重组。 二、拟设立的全资子公司基本情况 （一）公司名称：沃顿科技（南京）有限公司（暂定名，以工商 登记为准） （二）类型：有限责任公司 （三）注册资本：30,000 万元人民币 （四）注册地址：江苏省南京市江北新区 （五）经营范围：反渗透膜、纳滤膜及其他分离膜材料产品的研 发、生产、销售和技术服务；高分子材料、高分子助剂的研发、生 ...

证券代码：000920 证券简称：沃顿科技 公告编号：2025-062 沃顿科技股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券 交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公 司章程》的有关规定。 4、会议时间： （2）股东可委托授权代理人出席会议和参加表决，该受托人不必是公 司股东； （3）公司董事、高级管理人员，见证律师； （4）根据相关法规应当出席股东会的其他人员。 8、会议地点：贵州省贵阳市贵阳国家高新技术产业开发区黎阳大道 1518 号 102 五楼会议室。 （1）现场会议时间：2025 年 12 月 16 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时 间为 2025 年 12 月 16 日 9:15-9:2 ...

证券代码：000920 证券简称：沃顿科技 公告编号：2025-059 三、董事出席会议情况 公司实有董事 7 人，亲自出席会议董事 7 人，公司高级管理人员 列席了会议。 四、会议决议及议案表决情况 沃顿科技股份有限公司 第八届董事会第九次会议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议通知情况 沃顿科技股份有限公司（以下简称"公司"）董事会于 2025 年 11 月 13 日向全体董事、高级管理人员及相关人员发出了书面会议通知。 二、会议召开的时间、地点、方式 本次董事会会议于 2025 年 11 月 21 日在公司五楼会议室以现场 和通讯方式相结合的形式召开。会议由董事长蔡志奇先生主持。会议 的召集、召开符合有关法律、法规和《公司章程》的规定。 会议经过审议，作出了以下决议： （一）审议通过了《关于续聘 2025 年度审计机构的议案》。 同意：7 票；反对：0 票；弃权：0 票。 详见刊载于《证券时报》和"巨潮资讯网"的《关于拟续聘会计师 事务所的公告》（公告编号：2025-060）。 本议案在提交董事会审议前已经董事会审计委员会审议通 ...